BBCR BIO International Convention review

Tweet

 

Written by, Candida Fratazzi MD Clinical Strategy and Trial Design Specialist Boston Biotech Clinical Research

The last couple weeks have been busy but I am happy to say that all our work has paid off. The BIO International Convention in Washington DC was a great success. In the coming week, our entire slideshow will be available for viewing on website, but for now I’d like to share with you the highlights of our BBCR presentation.

To introduce you to our topic, I was the moderator for Biomarker Session #86 on Tuesday, June 28, titled Rare Diseases Experience as a Model to Critically Affect Innovation in Biomarker Strategy and Precision Medicine. Joining me were speakers:

Claudio Carini MD, PhD, FRCPath, Sr. Director, Translational Medicine, Pfizer Inc.;
Gloria Feuerstein MD, MSc, FAHA, President, Farmacon Consulting, LLC;
Mark Trusheim, President, Bioconsulting, LLC; and
Collin Williams PhD, Director, Thomson Reuters,

with Marc and Collin presenting on Rare Diseases as Stratified Medicine Economic Models and The Effective Use of Information Resources to Support Innovation, respectively. In one of the more insightful portions of our session, we asked the following questions in order to get the audience’s opinion on four major issues related to the topics covered.

1. Can Precision Medicine impact Health Care by reducing treatment cost and increasing the quality of treatments, both on safety and efficacy?
2. Can the clinical use of Diagnostic Markers drastically reduce drug related adverse events (AEs), and costly hospitalization?
3. Can the use of Biomarkers drastically reduce drug development’s cost, time and failure rate?
4. Can the Rare Diseases Model pave the way to innovation and acceleration of drug development of non-rare medical conditions?

This is what we found:

1. Can Precision Medicine impact Health Care by reducing treatment cost and increasing the quality of treatments, both on safety and efficacy?

2. Can the clinical use of Diagnostic Markers drastically reduce drug related adverse events (AEs), and costly hospitalization?

3. Can the use of Biomarkers drastically reduce drug development’s cost, time and failure rate?

4. Can the Rare Diseases Model pave the way to innovation and acceleration of drug development of non-rare medical conditions?

Almost everyone agreed that precision medicine could reduce treatment costs and improve quality, and the clinical use of diagnostic markers could drastically drug related AEs. But more than 30 percent disagreed that biomarkers could drastically reduce drug development costs and failure rates, or that the rare disease model could pave the way to innovation in drug development for non-rare conditions. Do you agree? Feel free to share your comments below. I am interested in knowing what your opinions are on these issues.

Thanks for visiting our blog and be sure to visit our site again soon when the full BIO Convention presentations will be available.